These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 1958262)

  • 1. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.
    Jellinger KA
    Mol Chem Neuropathol; 1991 Jun; 14(3):153-97. PubMed ID: 1958262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
    Jellinger KA
    J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative changes in some subcortical nuclei in aging, Alzheimer's disease and Parkinson's disease.
    Jellinger K
    Neurobiol Aging; 1987; 8(6):556-61. PubMed ID: 3323929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological substrates of dementia in parkinsonism. A critical update.
    Jellinger KA
    J Neural Transm Suppl; 1997; 51():57-82. PubMed ID: 9470129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological substrates of mental dysfunction in Lewy body disease: an update.
    Jellinger KA
    J Neural Transm Suppl; 2000; 59():185-212. PubMed ID: 10961431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathological substrates of Alzheimer's disease and Parkinson's disease.
    Jellinger K
    J Neural Transm Suppl; 1987; 24():109-29. PubMed ID: 3316494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in the pathology of Parkinson's disease.
    Jellinger K
    Adv Neurol; 1990; 53():1-16. PubMed ID: 1978509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.
    Hall H; Reyes S; Landeck N; Bye C; Leanza G; Double K; Thompson L; Halliday G; Kirik D
    Brain; 2014 Sep; 137(Pt 9):2493-508. PubMed ID: 25062696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological basis for neurotransmitter changes in Parkinson's disease.
    Mann DM; Yates PO
    Neuropathol Appl Neurobiol; 1983; 9(1):3-19. PubMed ID: 6133229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.
    Trillo L; Das D; Hsieh W; Medina B; Moghadam S; Lin B; Dang V; Sanchez MM; De Miguel Z; Ashford JW; Salehi A
    Neurosci Biobehav Rev; 2013 Sep; 37(8):1363-79. PubMed ID: 23707776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons.
    Mufson EJ; Presley LN; Kordower JH
    Brain Res; 1991 Jan; 539(1):19-30. PubMed ID: 1849779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
    Šaponjić J
    Glas Srp Akad Nauka Med; 2011; (51):85-97. PubMed ID: 22165729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases.
    Gaspar P; Gray F
    Acta Neuropathol; 1984; 64(1):43-52. PubMed ID: 6089493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease.
    Halliday GM; Li YW; Blumbergs PC; Joh TH; Cotton RG; Howe PR; Blessing WW; Geffen LB
    Ann Neurol; 1990 Apr; 27(4):373-85. PubMed ID: 1972319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications.
    Henderson JM; Carpenter K; Cartwright H; Halliday GM
    Brain; 2000 Jul; 123 ( Pt 7)():1410-21. PubMed ID: 10869053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The locus ceruleus and dementia in Parkinson's disease.
    Zweig RM; Cardillo JE; Cohen M; Giere S; Hedreen JC
    Neurology; 1993 May; 43(5):986-91. PubMed ID: 8492957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.
    Buddhala C; Loftin SK; Kuley BM; Cairns NJ; Campbell MC; Perlmutter JS; Kotzbauer PT
    Ann Clin Transl Neurol; 2015 Oct; 2(10):949-59. PubMed ID: 26478895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease.
    Yoshimura M
    Eur Neurol; 1988; 28 Suppl 1():29-35. PubMed ID: 3378559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of brain destruction in Parkinson's and Alzheimer's diseases.
    Braak H; Braak E; Yilmazer D; de Vos RA; Jansen EN; Bohl J
    J Neural Transm (Vienna); 1996; 103(4):455-90. PubMed ID: 9617789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pedunculopontine nucleus in Parkinson's disease.
    Zweig RM; Jankel WR; Hedreen JC; Mayeux R; Price DL
    Ann Neurol; 1989 Jul; 26(1):41-6. PubMed ID: 2549845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.